Summary
- Profile Type
- Technology offer
- POD Reference
- TOES20250217006
- Term of Validity
- 17 February 2025 - 17 February 2026
- Company's Country
- Spain
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Spanish neuropharmacology research group evaluates CNS-targeting drugs for depression, drug abuse, and neurodegenerative diseases. Their work includes behavioral analysis by sex and age, pharmacological interactions, and microbiome influence on treatments. They develop advanced drug delivery systems and molecular analysis tools to optimize therapies. Seeking partners for joint research, drug evaluation, and technology transfer.
- Full Description
-
A research group from Spain specialized in neuropharmacology offers advanced expertise in the preclinical evaluation of CNS-targeting drugs, focusing on mental health, and neurodegenerative diseases. Their multidisciplinary approach integrates cutting-edge drug screening techniques with innovative pharmaceutical technologies to address key challenges in CNS therapeutics.
Innovative Research Areas:
1. Behavioral characterization of novel therapeutic options (pharmacological and neuromodulators) considering biological sex and age as key independent factors, and with a special focus on adolescence as a vulnerable period for the emergence of psychiatric disorders.
2. Pharmacological interaction studies to optimize the combination of drug treatments for comorbid conditions.
3. Novel technological applications to enhance pharmacological treatments.
4. Molecular mechanisms underlying pharmacological effects.
5. The role of the microbiome in therapeutic response.
Technological Expertise and Know-How:
1. Animal Models of Psychopathology: Preclinical models for stress-related disorders, psychiatric comorbidities, substance abuse disorders, and neurodevelopmental conditions.
2. Behavioral Testing Batteries: Comprehensive assessments for affective, addictive, cognitive, and social behaviors to characterize drug responses.
3.Pharmaceutical Technology: Development of hydrogels and novel drug delivery systems for controlled release.
4.Brain-Microbiome Interaction: Pharmacological modulation and microbiological analysis of brain-gut interactions.
5.Molecular Biology Techniques: Analysis of molecular correlates of drug-induced behavioral responses.
6.Hormonal Influence on Therapeutic Response: Investigating the role of sex hormones in CNS drug efficacy.
Available Techniques In Vivo Studies: Animal Models.
1. Early-life stress, social isolation, premenstrual dysphoric disorder, ‘double-hit’ psychiatric comorbidities, and innate psychopathology models.
2. Behavioral Analysis in Experimental Animals:
- Affective-like Behaviors: Forced swim test, open field test, marble burying, novelty-suppressed feeding test, sucrose splash test, sucrose preference test, elevated plus maze, etc.
- Addictive-like Behaviors: Conditioned place preference, operant chambers, voluntary drug consumption tests, etc.
- Cognitive Behaviors: Barnes maze, novel object recognition, radial arm maze, etc. o Social Behaviors: Assessment of pro-social interactions.
3. Stereotaxic Surgery: Targeted drug administration and hormone-related surgeries (gonadectomy, etc.).
Innovative Solutions to Therapeutic Challenges
Conventional neuropharmacological strategies often lack comprehensive data on CNS-targeted therapies, particularly regarding long-term efficacy and safety. This research group overcomes such limitations through proprietary preclinical models that replicate complex neural interactions, allowing for more accurate predictions of therapeutic potential and toxicity. Their research has identified promising candidates with neuroprotective and antidepressant properties, supporting the development of safer and more effective treatments.
Collaboration Opportunities
The group seeks international partnerships with pharmaceutical companies, research institutions, and biotech firms to advance CNS drug development. Specific collaboration opportunities include:
- Joint Research Projects: Co-development of novel CNS-targeted therapies and drug delivery strategies.
- Drug Evaluation Partnerships: Expertise in therapeutic screening and toxicity profiling to optimize drug candidates.
- Technology Transfer Agreements: Providing validated methodologies and innovative drug delivery technologies to enhance R&D pipelines.
By collaborating with this research group, partners gain access to a robust preclinical and translational research platform, accelerating drug development timelines and enhancing the success rate of CNS-targeted therapies. - Advantages and Innovations
-
This research group from Spain stands at the forefront of neuropharmacology, offering comprehensive preclinical evaluation services for drugs targeting central nervous system (CNS) disorders, particularly those related to mental health such as depression, anxiety, drug abuse, etc., as well as neurodegenerative diseases. Their approach integrates advanced in vivo pharmacological screening with innovative drug delivery technologies to overcome key therapeutic challenges.
A distinguishing feature of their research is the behavioral characterization of novel therapeutic options, including both pharmacological agents and neuromodulators, considering biological sex and age-specific responses.
Their work also focuses on the optimization of combined treatments in comorbid conditions, studying diverse pharmacological interactions to improve therapeutic efficacy and safety. Additionally, they explore molecular mechanisms underlying drug effects, providing deeper insights into the pharmacodynamics of potential CNS therapies.
Beyond drug assessment, the group characterizes novel pharmaceutical technologies to optimize drug targeting, enhance bioavailability, and reduce systemic toxicity. Their expertise extends to the role of the microbiome in therapeutic response, aiming to personalize and refine treatment strategies based on individual microbiota profiles.
Their research has successfully identified candidate compounds with neuroprotective and antidepressant potential, contributing to numerous peer-reviewed publications that reinforce the scientific rigor of their work.
The group is actively seeking strategic partnerships with pharmaceutical companies, research institutions, and biotech firms to accelerate CNS-targeted drug development. They offer expertise in joint research, drug evaluation, and technology transfer, supporting the advancement of more effective and safer CNS therapies. - Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 9: Industry, Innovation and Infrastructure
- IPR status
- No IPR applied
Partner Sought
- Expected Role of a Partner
-
The research group is seeking collaborations with pharmaceutical companies, biotechnology firms, and research institutions that focus on central nervous system (CNS) disorders. Industry partners engaged in drug development, particularly in neuropharmacology and advanced drug delivery, are highly desirable.
Activity:
The ideal partner should be active in CNS therapeutics, drug discovery, or pharmaceutical technology innovation. Expertise in neurodegenerative diseases, depression, or drug abuse treatment would be particularly relevant. Companies working on drug formulation, bioavailability enhancement, or preclinical evaluation are also of interest.
The partner is expected to engage in one or more of the following roles:
- Joint Research Projects: Co-developing CNS-targeted therapies or novel drug delivery systems.
- Drug Evaluation Partnerships: Leveraging the research group's expertise in therapeutic screening and toxicity assessment to optimize drug candidates.
- Technology Transfer Agreements: Adopting or integrating the group's proprietary drug delivery technologies into their R&D pipelines.
By collaborating, partners will gain access to cutting-edge preclinical models and drug delivery innovations, accelerating drug development and enhancing the safety and efficacy of CNS therapeutics. - Type and Size of Partner
- SME <=10
- R&D Institution
- SME 11-49
- Big company
- University
- SME 50 - 249
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001014 - Neurology, Brain Research
- 03004007 - Pharmaceutics
- 06001015 - Pharmaceutical Products / Drugs
- 06002002 - Cellular and Molecular Biology
- Market keywords
- 05003005 - Drug delivery and other equipment
- 05007002 - Pharmaceuticals/fine chemicals
- 04006 - Cellular and Molecular Biology
- Targeted countries
- All countries